Hydroxyurea for children with sickle cell disease in sub‐Saharan Africa: A summary of the evidence, opportunities, and challenges
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-05 · 43 (5) · 430-441
DOI: 10.1002/phar.2792 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 26.03.2023. Verfasst von Daniel Dexter und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medway Maritime Hospital, Kent, UK. Hauptthemen laut MEDLINE: Hydroxyurea, Anemia, Sickle Cell. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: National Heart, Lung, and Blood Institute.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Sickle cell disease (SCD) is a common and life‐threatening inherited blood disorder that affects more than 300,000 newborns per year. Because of the origins of the sickle gene mutation as a protective mechanism against malaria for those with sickle cell trait, more than 90% of annual SCD births are in sub‐Saharan Africa (sSA). Over the past several decades, there have been many important advances in the care of individuals with SCD, including early diagnosis through newborn screening programs (NBS), prophylactic penicillin, the development of vaccines to prevent invasive bacterial infections, and the emergence of hydroxyurea as the primary disease‐modifying pharmacologic therapy. These relatively simple and inexpensive interventions have significantly reduced the morbidity and mortality of sickle cell anemia (SCA) such that individuals with SCD can live longer and more complete lives. Unfortunately, although these interventions are relatively inexpensive and evidence‐based, they are only readily available for affected individuals living in high‐income settings, representing 90% of the global SCD burden exists, SCD still results in early mortality with 50–90% of infants likely dying before reaching 5 years of age. Recently, there are an increasing number of efforts in many African countries to prioritize SCA with pilot NBS programs, improved diagnostics, and expanded SCD education for health care professionals and the general public. It is essential to include access to hydroxyurea as a core component of any SCD care program, but there are still many barriers that prevent the widespread global use of hydroxyurea. Here, we summarize what we know about SCD and hydroxyurea use in Africa and discuss a strategy to respond to what we consider to be a public health imperative to maximize access to and appropriate use of hydroxyurea for all individuals with SCD using innovative dosing and monitoring strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medway Maritime Hospital, Kent, UK.
- Lifespan Comprehensive Sickle Cell Center, Hasbro Children's Hospital, Providence, Rhode Island, USA.
- Department of Pediatrics, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
ORCID-Profile: Patrick T McGann
Förderung
- National Heart, Lung, and Blood Institute
Zitieren
APA
Dexter, D., & McGann, P. T. (2023). Hydroxyurea for children with sickle cell disease in sub‐Saharan Africa: A summary of the evidence, opportunities, and challenges. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(5), 430-441. https://doi.org/10.1002/phar.2792
Vancouver
Dexter D, McGann PT. Hydroxyurea for children with sickle cell disease in sub‐Saharan Africa: A summary of the evidence, opportunities, and challenges. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(5):430-441. doi:10.1002/phar.2792
BibTeX
@article{Dexter2023,
author = {Dexter, Daniel and McGann, Patrick T},
title = {Hydroxyurea for children with sickle cell disease in sub‐Saharan Africa: A summary of the evidence, opportunities, and challenges},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
volume = {43},
number = {5},
pages = {430--441},
doi = {10.1002/phar.2792}
}
EUVIMED